Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

Immunotherapy uses a person's own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy ...

Amplia Therapeutics and Immutep have released clinical trial results that promise more effective treatments for pancreatic and lung cancers ...

Like cancer, placental cells multiply rapidly, invade tissues, and evade destruction by the immune system, but maternal ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

A new study of 18,932 metastatic colorectal cancer patients reveals that microsatellite instability, albumin levels, and ...

UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

A dedicated onconephrology service at Brigham and Women’s Hospital has improved kidney outcomes in patients treated for ...

KL Krems study shows that higher radiation doses in lung cancer treatment carry no added risk of inflammation – and may improve survival: Krems Wednesday, May 14, 2025, 14:00 Hr ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...

CytoDyn (OTCQB:CYDY) said on Tuesday that data supports a new way its drug leronlimab, a CCR5 antagonist, may help treat ...